

Kyowa Hakko Kirin Co., Ltd.**Appendix to the Fiscal 2010 Interim Consolidated Financial Statements**

(January 1, 2010 - June 30, 2010)

Index	Page
I. Consolidated Financial Results	
1. Income	1
2. Results by segment	1
3. Other income	2
4. Extraordinary income/losses	2
5. R&D expenses	2
6. Capital expenditure	3
7. Depreciation expenses	3
8. Key indicators	3
II. Consolidated Subsidiaries and Affiliates	4
III. Non-Consolidated Net Sales by Division	5
1. Kyowa Hakko Kirin	5
2. Kyowa Hakko Bio	6
3. Kyowa Hakko Chemical	6
R&D Pipeline	7

This document was made as a supplement to the Kessan Tanshin (financial report) for the interim period of the fiscal year ending December 31, 2010. This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.

I. Consolidated Financial Results

1. Trends in income

Millions of yen, rounded down

	(Ref: 2009)	April 1, 2009 to December 31, 2009		(Ref: 2009)	January 1, 2010 to December 31, 2010			
	January 1 to June 30 results (A)	April 1 to September 30 results	April 1 to December 31 results	January 1 to December 31 results	January 1 to June 30 results (B)	Change on January to June 2009		January to December forecast
						Amount (B-A)	%	
Net sales	194,722	194,395	309,111	407,017	203,466	8,744	104%	407,000
Gross Profit	84,945	89,844	139,739	180,167	92,763	7,818	109%	--
Selling, general and administrative expenses	71,213	69,064	111,496	149,232	71,071	(141)	100%	--
Operating income (prior to amortization of goodwill)	18,457	25,431	35,221	40,311	26,344	7,887	143%	46,803
Operating income	13,732	20,779	28,243	30,934	21,692	7,960	158%	37,500
Other income	4,593	3,372	4,012	6,147	3,120	(1,472)		--
Other expenses	2,631	1,950	2,776	4,455	2,478	(152)		--
Recurring income	15,693	22,201	29,479	32,626	22,334	6,640	142%	39,000
Extraordinary income	6,075	--	27	6,102	1,082	(4,993)		--
Extraordinary expenses	9,303	1,801	8,878	16,447	5,775	(3,527)		--
Net income before income taxes	12,466	20,400	20,628	22,282	17,641	5,175	142%	34,000
Corporate, local and enterprise taxes	5,562	9,423	11,631	12,210	7,718	2,155		--
Income from minority interests	(38)	165	199	31	21	60		--
Net income	6,942	10,811	8,797	10,040	9,901	2,958	143%	20,000
EPS before goodwill amortization (¥/share)	20.34	27.05	27.63	33.97	25.55			51.45

*As a result of the change in fiscal year end, the figures used for comparison the above 2009 January 1 to June 30 results are the sum of the figures from the three month period from January 1 to March 31, 2009, obtained by subtracting figures for the nine month period (April 1, 2009 to December 31, 2009) from the figures for the twelve month period to March 2009, and the figures from the first quarter of the fiscal year ending December 31, 2009. Also please note that figures for the Food segment are included in the reference figures for January 1 to March 31, 2009.

2. Trends in results by segment

(1) Results by operating segment

Millions of yen, rounded down

	(Ref: 2009)	April 1, 2009 to December 31, 2009		(Ref: 2009)	January 1, 2010 to December 31, 2010			
	January 1 to June 30 results (A)	April 1 to September 30 results	April 1 to December 31 results	January 1 to December 31 results	January 1 to June 30 results (B)	Change on January to June 2009		January to December forecast
						Amount (B-A)	%	
Net sales	194,722	194,395	309,111	407,017	203,466	8,744	104%	407,000
Pharmaceuticals	101,323	103,968	158,273	207,384	103,475	2,152	102%	205,000
Bio-Chemicals	42,063	41,417	69,751	90,670	44,186	2,122	105%	84,000
Chemicals	26,916	32,854	52,326	64,208	61,289	34,373	228%	128,000
Food	9,633	--	--	9,633	--	(9,633)	--%	--
Other	28,427	28,927	49,500	63,731	5,082	(23,344)	18%	10,000
Total	208,363	207,168	329,851	435,628	214,034	5,670	103%	427,000
Eliminations	(13,641)	(12,772)	(20,740)	(28,611)	(10,567)	3,073	77%	(20,000)
Operating income	13,732	20,779	28,243	30,934	21,692	7,960	158%	37,500
*Before goodwill amortization	18,457	25,431	35,221	40,311	26,344	7,887	143%	46,803
Pharmaceuticals	16,739	21,363	26,657	31,826	17,993	1,253	107%	29,000
	21,054	25,677	33,129	40,455	22,307	1,253	106%	37,628
Bio-Chemicals	2,194	1,665	3,048	3,965	1,853	(341)	84%	4,000
	2,507	1,978	3,517	4,590	2,166	(341)	86%	4,625
Chemicals	(5,653)	(2,486)	(1,984)	(5,564)	1,589	7,242	(28%)	4,000
	(5,628)	(2,462)	(1,947)	(5,514)	1,614	7,242	(29%)	4,049
Food	87	--	--	87	--	(87)	--%	--
	161	--	--	161	--	(161)	--%	--
Other	218	170	400	434	150	(67)	69%	500
	218	170	400	434	150	(67)	69%	500
Total	13,588	20,712	28,122	30,750	21,587	7,999	159%	37,500
	18,313	25,363	35,100	40,127	26,239	7,926	143%	46,803
Eliminations	143	67	121	184	105	(38)	73%	--

Notes: 1. Figures representing amounts before goodwill amortization have been italicized.

2. Results of subsidiaries Miyako Kagaku Co., Ltd., and Kashiwagi Corporation, are reported under the Chemicals segment rather than the Other segment as of the January 1, 2010 to December 31, 2010 period.

(2) Overseas sales

Millions of yen, rounded down

	(Ref: 2009)		April 1, 2009 to December 31, 2009				(Ref: 2009)		January 1, 2010 to December 31, 2010	
	January 1 to June 30 results	Percentage of consolidated sales	April 1 to September 30 results	Percentage of consolidated sales	April 1 to December 31 results	Percentage of consolidated sales	January 1 to December 31 results	Percentage of consolidated sales	January 1 to June 30 results	Percentage of consolidated sales
Overseas sales	32,286	16.6%	39,725	20.4%	63,367	20.5%	77,209	19.0%	42,236	20.8%
America	8,559	4.4%	10,688	5.5%	16,849	5.5%	20,670	5.1%	12,977	6.4%
Europe	10,509	5.4%	11,309	5.8%	18,524	6.0%	23,038	5.7%	10,779	5.3%
Asia	12,922	6.6%	17,420	9.0%	27,415	8.9%	32,709	8.0%	18,114	8.9%
Other regions	294	0.2%	306	0.2%	578	0.2%	790	0.2%	364	0.2%
Total consolidated net sales	194,722	100.0%	194,395	100.0%	309,111	100.0%	407,017	100.0%	203,466	100.0%

3. Trends in Other Income

Millions of yen, rounded down

	(Ref: 2009) January 1 to June 30 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010
		April 1 to September 30 results	April 1 to December 31 results		January 1 to June 30 results
Other income	4,593	3,372	4,012	6,147	3,120
Interest received	311	249	443	597	221
Dividend income	2,461	1,125	914	2,333	485
Foreign exchange gain	135	--	--	135	--
Income from equity method investments	959	945	1,558	1,774	626
Other	724	1,051	1,095	1,306	1,787
Other expenses	2,631	1,950	2,776	4,455	2,478
Interest expense	193	153	244	354	122
Foreign exchange loss	(349)	503	112	(443)	1,143
Loss from disposal of fixed assets	1,574	843	1,163	2,441	608
Other	1,213	449	1,255	2,103	604

4. Trends in Extraordinary Income / Losses

Millions of yen, rounded down

	(Ref: 2009) January 1 to June 30 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010
		April 1 to September 30 results	April 1 to December 31 results		January 1 to June 30 results
Extraordinary income	6,075	--	27	6,102	1,082
Gain from occurrence of goodwill	--	--	--	--	854
Gain on sale of investment securities	--	--	--	--	120
Allowance for doubtful accounts	--	--	--	--	107
Gain on sale of fixed assets	--	--	27	27	--
Gain on sale of shares in affiliates	4,721	--	--	4,721	--
Gain of sale of investments in affiliates	1,354	--	--	1,354	--
Extraordinary losses	9,303	1,801	8,878	16,447	5,775
Loss from revaluation of investment securities	1,722	421	537	1,905	2,588
Loss on revision to retirement benefit system	--	--	--	--	1,771
Extraordinary depreciation of fixed assets	--	--	3,299	3,299	1,225
Loss from sale of fixed assets	--	--	--	--	189
Asset impairment losses	3,793	--	2,671	6,464	--
Loss from change in equity affiliates	1,379	1,379	1,379	1,379	--
Loss from sale of investment securities	--	--	991	991	--
Integration-related expenses	1,429	--	--	1,429	--
Other	977	--	--	977	--

5. Trends in R&D Expenses

Billions of yen, rounded down

	(Ref: 2009) January 1 to June 30 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010	
		April 1 to September 30 results	April 1 to December 31 results		January 1 to June 30 results	January 1 to December 31 forecast
R&D (Consolidated)	20.8	19.7	34.9	46.4	21.4	47.0
R&D to net sales ratio	10.7%	10.2%	11.3%	11.4%	10.5%	11.6%
Pharmaceuticals	18.3	17.5	31.6	41.6	19.3	42.1
(R&D to net sales ratio)	18.1%	16.9%	20.0%	20.1%	18.7%	20.6%
Bio-Chemicals	1.7	1.6	2.5	3.4	1.5	3.7
Chemicals	0.5	0.5	0.7	1.0	0.4	1.0
Food	0.2	--	--	0.2	--	--
Other	--	--	--	--	--	--

6. Trends in Capital Expenditure (Tangible fixed assets)

Billions of yen, rounded down

	(Ref: 2009) January 1 to June 30 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010	
		April 1 to September 30 results	April 1 to December 31 results		January 1 to June 30 results	January 1 to December 31 forecast
Capital expenditure (Consolidated)	14.0	15.3	24.0	29.6	12.2	26.5
Pharmaceuticals	9.3	9.4	15.4	19.5	7.0	13.5
Bio-Chemicals	3.2	3.3	4.9	6.4	3.7	9.8
Chemicals	2.8	2.5	3.5	4.9	1.3	3.1
Food	0.0	--	--	0.0	--	--
Other	0.0	0.0	0.0	0.0	--	0.0
Eliminations	(1.5)	(0.0)	(0.0)	(1.5)	--	--

7. Trends in Depreciation Expenses

Billions of yen, rounded down

	(Ref: 2009) January 1 to June 30 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010	
		April 1 to September 30 results	April 1 to December 31 results		January 1 to June 30 results	January 1 to December 31 forecast
Depreciation expenses (Consolidated)	8.4	8.6	17.0	21.4	10.5	22.9
Pharmaceuticals	3.4	3.8	9.2	10.9	4.5	11.5
Bio-Chemicals	2.5	2.6	4.3	5.5	3.8	6.6
Chemicals	2.0	2.1	3.3	4.4	2.1	4.7
Food	0.2	--	--	0.2	--	--
Other	0.0	0.0	0.1	0.1	0.0	0.0
Eliminations	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	--

8. Trends in Key Indicators

(1) Exchange rate

	(Ref: 2009) January 1 to June 30 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010	
		April 1 to September 30 results	April 1 to December 31 results		January 1 to June 30 results	January 1 to December 31 forecast
US Dollar (¥/US\$)	95	96	94	94	91	91
Euro (¥/Euro)	127	133	133	130	121	116

(2) Operating indicators (Consolidated)

	April 1, 2009 to December 31, 2009		January 1 to December 31, 2010
	April 1 to September 30 results	April 1 to December 31 results	January 1 to June 30
(prior to amortization of goodwill)	27.05	27.63	25.55
Net income per share (yen)	18.91	15.41	17.38
Operating income to sales ratio (%)	10.7%	9.1%	10.7%
Total assets (million yen)	716,199	695,268	679,685
Net assets (million yen)	547,942	540,343	540,565
Equity ratio (%)	75.9	77.1	79.4
Net assets per share (yen)	953.91	940.79	946.77
Number of staff at end of term	7,443	7,436	7,554

II. Consolidated Subsidiaries and Affiliates

(As of June 30, 2010)

Segment	Type	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
		Kirin Kunpeng (China) Bio- Pharmaceutical Co., Ltd.	100.0%	Manufacture and sale of pharmaceuticals (China)
		Kyowa Medical Promotion Co., Ltd.	100.0%	Sales promotion of pharmaceuticals
		Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		BioWa, Inc.	100.0%	Out-licensing and promotion of anti-body technology (US)
		Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of outsourced pharmaceutical products
		Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
		Hematech, Inc.	100.0%	Technology research for manufacture of therapeutic antibody (US)
		Hematech-GAC Venture, LLC	51.0%	Technology research for manufacture of therapeutic antibody (US)
		Kyowa Hakko Kirin Italia S.r.l.	100.0%	Sales of pharmaceuticals (Italy)
		Jeil-Kirin Pharmaceutical Inc.	90.0%	Sales of pharmaceuticals (Korea)
		Kyowa Kirin Pharmaceuticals (Taiwan) Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)
		Kyowa Hakko Kirin (Hong Kong) Co., Ltd.	100.0%	Sales of pharmaceuticals (Hong Kong)
Kyowa Hakko Kirin (Singapore) Pte. Ltd.	100.0%	Sales of pharmaceuticals (Singapore)		
Bio-Chemicals	Consolidated subsidiary	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
		Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
		Biokyowa Inc.	100.0%	Manufacture and sale of amino acids (US)
		Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China)
		Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US)
		Kyowa Hakko Europe GMBH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany)
		Kyowa Italiana Farmaceutici S.r.l.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy)
		Kyowa Hakko (H.K.) Co., Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Hong Kong)
		Kyowa Hakko Bio Singapore Pte. Ltd. (*1)	100.0%	Sale and import/export of fine chemicals including amino acids (Singapore)
		Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		Kyowa Wellness Co., Ltd.	100.0%	Sale of healthcare products
Chemicals	Consolidated subsidiary	Kyowa Hakko Chemical Co., Ltd.	100.0%	Manufacture and sale of chemicals
		Miyako Kagaku Co., Ltd.	100.0%	Wholesale sales of pharmaceutical raw materials, chemicals, foods, etc.
		Kashiwagi Corporation	100.0%	Wholesale sales of chemicals, food, etc.
Chemicals	Affiliate accounted for by the equity method	J-PLUS Co., Ltd.	50.0%	Manufacture and sale of plasticizers
		Kurogane Kasei Co., Ltd.	40.0%	Manufacture and sale of plasticizers, fine chemicals, etc.
Other	Consolidated subsidiary	Chiyoda Kaihatsu Co., Ltd.	100.0%	Transportation, insurance, wholesale sales of food, etc.
		Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol
	Affiliate accounted for by the equity method	Kirin Kyowa Foods Company, Limited	35.0%	Manufacture and sale of seasonings, confectionery and bread products
		Kyowa F.D. Foods Co., Ltd.	35.0%	Manufacture and sale of freeze-dried foods
		Kirin Ohland Foods Co., Ltd.	35.0%	Manufacture and sale of bakery products, etc.
		Kyowa HiFoods Co. Ltd.	35.0%	Import and sale of foods, etc.
		Aji-Nihon Co., Ltd.	16.2%	Manufacture and sale of foods and seasonings, etc.
Zenmi Foods Inc.	17.5%	Manufacture and sale of seasonings		

Notes: 1. Changes to the scope of consolidation

Newly consolidated: Two companies: Kyowa Italiana Farmaceutici S.r.l. and Kyowa Hakko Bio Singapore Pte. Ltd.

2. As of the January 1, 2010 to December 31, 2010 period Miyako Kagaku Co., Ltd., and Kashiwagi Corporation are reported under the Chemicals segment rather than the Other segment.

III. Non-Consolidated Net Sales by Division (Items and main products)

1. Kyowa Hakko Kirin

Billions of yen, rounded down

Pharmaceuticals division (non-consolidated)	(Ref: 2009) January 1 to June 30 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010	
		April 1 to September 30 results	April 1 to December 31 results		January 1 to June 30 results	January 1 to December 31 forecast
Pharmaceutical division total	91.5	94.9	143.9	187.6	94.1	188.6
Central nervous system agents						
<i>Depakene</i>	5.3	5.7	8.8	11.2	5.2	11.0
<i>Topina</i>	0.6	0.8	1.2	1.5	0.9	1.9
Sensory organ agents						
<i>Patanol</i>	5.3	1.9	3.0	7.4	4.7	7.5
Circulatory organ agents						
<i>Coniel</i>	11.0	11.7	18.3	23.3	10.3	21.3
<i>Inovan / Pre Dopa</i>	1.7	1.7	2.7	3.5	1.5	3.3
<i>Coversyl</i>	2.3	2.4	3.7	4.8	2.0	4.4
Digestive organ agents						
<i>Nauzelin</i>	2.5	2.4	3.8	5.1	2.6	5.3
Other agent affecting metabolism						
<i>Nesp/Espo</i>	22.1	25.7	39.6	48.9	23.4	48.3
<i>Regpara</i>	2.9	3.4	5.5	6.8	4.3	8.6
Agents relating to blood and body fluids						
<i>Gran/Neu-up*2</i>	7.6	8.9	13.8	17.0	7.3	15.1
Anticancer agents						
<i>Farmorubicin / Adriacin</i>	3.2	3.3	4.9	6.4	2.4	5.5
<i>5 – FU (all types)</i>	1.7	1.9	2.9	3.7	1.5	2.7
<i>Navelbine</i>	1.5	1.5	2.2	2.9	1.0	2.6
Antiallergic agents						
<i>Allelock</i>	15.2	10.9	17.3	26.7	13.9	26.0
<i>Celtect</i>	1.8	1.5	2.3	3.3	1.4	2.7
Exports and Technology Out-Licensing	8.4	11.7	15.1	18.0	13.1	22.6

Notes 1: Results based on settlement price on a shipment basis. Forecasts are based on an actual consumption basis.

2: As of March 1, 2010, manufacturing, sales and other rights for Neu-up will be transferred to Yakult Honsha. Therefore, Gran/Neu-up figures after March 31, 2010 include only sales figures for Gran.

2. Kyowa Hakko Bio

Billions of yen, rounded down

Bio-Chemicals division (non-consolidated)	(Ref: 2009) January 1 to June 30 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010	
		April 1 to September 30 results	April 1 to December 31 results		January 1 to June 30 results	January 1 to December 31 forecast
Bio-Chemical division total	26.7	27.0	42.3	55.4	28.7	52.2
Pharmaceuticals / Industrial raw materials						
Amino acids	9.2	9.4	14.8	19.1	10.8	19.5
Nucleic acids and vitamins	2.0	2.1	3.5	4.5	2.5	4.9
Health care products	4.0	4.2	6.5	8.4	4.9	9.0
Agrochemicals, livestock and fisheries products*1	1.8	1.5	2.1	3.2	1.4	1.9
Alcohol*2	4.5	4.8	7.8	9.8	4.1	7.6

Notes 1. As of April 1, 2010 the domestic livestock and fisheries industry product sales operations of Kyowa Hakko Bio Co., Ltd. have been transferred to Aska Pharmaceuticals Co., Ltd.

2. On July 1, 2010, the Kyowa Hakko Bio Co., Ltd. alcohol business is scheduled to be transferred to Daiichi Alcohol Co. Ltd., a joint venture with Mercian Corporation (planned investment ratio: 35%).

3. Kyowa Hakko Chemical

Billions of yen, rounded down

Chemicals division (non-consolidated)	(Ref: 2009) January 1 to June 30 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010	
		April 1 to September 30 results	April 1 to December 31 results		January 1 to June 30 results	January 1 to December 31 forecast
Chemicals division total	26.8	32.8	52.3	64.2	39.7	84.9
Solvents	11.5	14.5	22.6	27.2	15.9	34.5
Raw materials for plasticizers	7.6	9.9	16.3	19.8	12.2	27.4
Specialty chemicals	6.3	6.8	11.3	14.5	9.9	20.0

R&D PIPELINES

Phase II, Phase III

Jul 28th 2010

Category	Code Name Product Name	Generic Name	Stage		Indication	Formulation	In-house or Licensed	Remarks
			Japan	Other countries				
Cancer/Hematology	KW-0761		Phase II	Phase I / II a in USA	Cancer (Hematologic tumor)	Injection	Developed In-house	Humanized monoclonal antibody (※)
	KRN321 NESP	Darbepoetin Alfa	Filed Nov/2008		☆ Chemotherapy induced anemia	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein Launched in Japan for anemia of CKD patients on dialysis from July 2007.
	AMG531	Romiplostim	Filed Mar/2010		Immune thrombocytopenic purpura	Injection	Kirin-Amgen	Thrombopoiesis stimulating protein
	KW-2246	Fentanyl citrate	Filed Feb/2010		Cancer pain	Sublingual tablet	Licensed from Orexo	
	KRN125	Pegfilgrastim		Phase II	Neutropenia	Injection	Kirin-Amgen	Long-acting G-CSF
	ARQ 197			Phase II	Cancer (Gastric cancer)	Oral	Licensed from ArQule	
Kidney	KRN321 NESP	Darbepoetin Alfa	Approved Apr/2010		☆ Anemia (not on dialysis)	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein Launched in Japan for anemia of CKD patients on dialysis
				Phase II in China	☆ Anemia (on dialysis)			
	KRN1493 REGPARA	Cinacalcet Hydrochloride		Phase III in China	secondary hyperparathyroidism	Oral	Licensed from NPS	Japan: Already launched
Immunology/Allergy	KW-4679 ALLOCK	Olopatadine Hydrochloride		Approved in China Jul/2010	Allergy	Oral	Developed In-house	Japan: Already launched
CNS	KW-6002	Istradefylline	Phase III	Licensed-out Jun/2010	Parkinson's disease	Oral	Developed In-house	Entered into a license agreement with Biovail Laboratories International SRL
	KW-6500	Acamprophane Hydrochloride	Phase III		Parkinson's disease	Injection	Licensed from Britannia Pharma.	

Phase I

Category	Code Name Product Name	Generic Name	Stage		Indication	Formulation	In-house or Licensed	Remarks
			Japan	Other countries				
Cancer/Hematology	KW-2450			Phase I in USA	Cancer	Oral	Developed In-house	
	KW-2478			Phase I / II a in EU/US	Cancer	Injection	Developed In-house	
	KRN330			Phase I / II a in USA	Cancer	Injection	Developed In-house	Fully human monoclonal antibody
	BIW-8962			Phase I / II a in USA	Cancer	Injection	Developed In-house	Humanized monoclonal antibody
	KRN951			Phase I	Cancer	Oral	Developed In-house	
Immunology/Allergy	KHK4563		Phase I		Asthma	Injection	Developed In-house	Humanized monoclonal antibody Being developed by MedImmune as MEDI-563 worldwide except in Japan and other Asian countries
	Z-206 ASACOL	Mesalazine	Phase I		☆ Crohn's disease	Oral <small>(pH dependent controlled-release formulation)</small>	Licensed from Zeria Pharma.	Jointly developed with Zeria Pharma Launched in Japan for ulcerative colitis from December, 2009.
	ASKP1240			Phase I	Organ Transplant Rejection	Injection	Developed with Astellas.	Fully human monoclonal antibody
Other	KW-3357	Antithrombin	Phase I	Phase I in Europe	Disseminated intravascular coagulation, Congenital antithrombin deficiency	Injection	Developed In-house	Recombinant antithrombin product
	KRN23			Phase I in USA	X-linked Hypophosphatemic rickets/osteomalacia (XLH)	Injection	Developed In-house	Fully human monoclonal antibody

(※) KW-0761 is outlicensed to Amgen Inc. on March 6th, 2008, with an exclusive right to develop and commercialize KW-0761 worldwide, except in Japan, Korea, China and Taiwan. Kyowa Hakko Kirin has retained the development and commercialization rights in these countries. Amgen has initially acquired the rights in all non-oncology indications, and Kyowa Hakko Kirin will continue its development activities in oncology until the completion of Phase IIa. At that time, Amgen may elect to reimburse Kyowa Hakko Kirin for its oncology-related development costs, expand its license to include oncology and assume the development and commercialization of KW-0761 in oncology settings.

(Note)
In Philippines, an NDA of Filgrastim(G-CSF) has been filed for neutropenia. In Vietnam, an NDA of Pegfilgrastim(long-G-CSF) has been filed.
In Korea, Taiwan and Hong Kong/Macau, NESP(long-acting erythropoiesis stimulating protein) was approved. In Thailand, Singapore, Malaysia and Philippines, an NDA of NESP has been filed. In India, NESP is currently in phase 3 clinical trial.
In Korea, Taiwan and Hong Kong/Macau, REGPARA(regulator of parathyroid gland) was approved. In Singapore, an NDA of REGPARA has been filed.

Updated since April 28th, 2010 (Area, Stage, Filed, Approved, Launched etc.)

★

New indication

Discontinued

Category	Code Name Product Name	Generic Name	Stage		Indication	Formulation	In-house or Licensed	Reason
			Japan	Other countries				
Cancer/Hematology	KRN654	anagrelide hydrochloride	Phase I / II		Essential thrombocythemia	Oral	Licensed from Shire.	Succeeded to Shire based on portfolio re-assessment
	KW-2449			Phase I / II a in USA	Cancer	Oral	Developed In-house	Based on portfolio re-assessment